歡迎選擇我們，上海恒遠(yuǎn)生物科技有限公司！免費(fèi)服務(wù)熱線：400-0899-208 防偽查詢(xún)

語(yǔ)言：Eng

您當(dāng)前的位置：: 首頁(yè)>; 產(chǎn)品中心>; 抗體>; 重組抗體>; CD163 Antibody

重組抗體

CD163 Antibody

　　恒遠(yuǎn)生物抗體平臺(tái)現(xiàn)已擁有4萬(wàn)多種抗體(含單抗和多抗)，包括人類(lèi)常用抗體，模式生物類(lèi)相關(guān)抗體、小分子抗體、二抗、標(biāo)簽抗體及內(nèi)參抗體等。并以每年4000種的速度在持續(xù)增長(zhǎng)。

　　恒遠(yuǎn)生物擁有專(zhuān)業(yè)的質(zhì)控團(tuán)隊(duì)，配備先進(jìn)實(shí)驗(yàn)儀器，現(xiàn)已成功地建立了ChIP平臺(tái)，因此我們的抗體不僅能提供Biotin、FITC、HRP等標(biāo)記，大部分抗體都能進(jìn)行ELISA、WB、IHC、IF、IP、ChIP等應(yīng)用驗(yàn)證。

　　我們致力于為所有用戶(hù)提供高親和力、高特異性的優(yōu)質(zhì)抗體，歡迎來(lái)電咨詢(xún)。

產(chǎn)品詳情相關(guān)產(chǎn)品

CD163 Antibody

貨號(hào)：

HYK-200291
規(guī)格：
圖片：
IHC image of CSB-RA801238A0HU diluted at 1:100 and staining in paraffin-embedded human lung tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

IHC image of CSB-RA801238A0HU diluted at 1:100 and staining in paraffin-embedded human spleen tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

產(chǎn)品詳情

Uniprot No.：

Q86VB7
基因名：

CD163
別名：

C163A_HUMAN antibody; CD 163 antibody; CD163 antibody; CD163 antigen antibody; CD163 molecule antibody; Hemoglobin scavenger receptor antibody; M130 antibody; M130 antigen precursor antibody; Macrophage associated antigen antibody; MM130 antibody; OTTHUMP00000238617 antibody; OTTHUMP00000238618 antibody; OTTHUMP00000238619 antibody; OTTHUMP00000238620 antibody; SCARI1 antibody; Scavenger receptor cysteine rich type 1 protein M130 antibody; sCD163 antibody; Soluble CD163 antibody
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類(lèi)型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC, FC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:500

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Flow cytometry (FC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

ACTA1 Antibody

CD97 Antibody

Phospho-RPS6KA1 (T359+S363) Antibody

Phospho-RB1 (S807) Antibody

Phospho-MYB (S11) Antibody

在線詢(xún)價(jià)

*
*
*
*
留言?xún)?nèi)容 *
*

上一篇：ACTA1 Antibody: 下一篇：CD74 Antibody

CD34 Antibody

恒遠(yuǎn)生物抗體平臺(tái)現(xiàn)已擁有4萬(wàn)多種抗體(含單抗和多抗),包括人類(lèi)常用抗體,模式生物類(lèi)相關(guān)抗體、小分子抗體、二抗、標(biāo)簽抗體及內(nèi)參抗體等。并以每年4000種的速度在持續(xù)增長(zhǎng)。

查看詳細(xì)

: Mono-methyl-Histone H3.1(R17)Antibody

Mono-methyl-Histone H3.1(R17)Antibody

查看詳細(xì)

: 組織胺H4受體抗體（HRH4/GPCR105）

恒遠(yuǎn)生物抗體平臺(tái)現(xiàn)已擁有4萬(wàn)多種抗體(含單抗和多抗)，包括人類(lèi)常用抗體，模式生物類(lèi)相關(guān)抗體、小分子抗體、二抗、標(biāo)簽抗體及內(nèi)參抗體等。并以每年4000種的速度在持續(xù)增長(zhǎng)。恒遠(yuǎn)生物擁有專(zhuān)業(yè)的質(zhì)控團(tuán)隊(duì)，配備先進(jìn)實(shí)驗(yàn)儀器，現(xiàn)已成功地建立了ChIP平臺(tái)，因此我們的抗體不僅能提供Biotin、FITC、HRP等標(biāo)記，大部分抗體都能進(jìn)行ELISA、WB、IHC、IF、IP、ChIP等應(yīng)用驗(yàn)證。我們致力于為所有用戶(hù)提供高親和力、高特異性的優(yōu)質(zhì)抗體，歡迎來(lái)電咨詢(xún)。

查看詳細(xì)

51bl,小草黄色电影网站,美女午夜操逼,免费国产精品中文字幕

重組抗體

CD163 Antibody

產(chǎn)品詳情

在線詢(xún)價(jià)

相關(guān)產(chǎn)品

CD34 Antibody

Mono-methyl-Histone H3.1(R17)Antibody

組織胺H4受體抗體（HRH4/GPCR105）

產(chǎn)品中心

最新新聞